Professor Cai-Cun Zhou: KRAS G12D Inhibitor HRS-4642 Shows Encouraging Activity in Late-Stage Solid Tumors with KRAS G12D Mutation

Professor Cai-Cun Zhou: KRAS G12D Inhibitor HRS-4642 Shows Encouraging Activity in Late-Stage Solid Tumors with KRAS G12D Mutation

2024.02.22
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Tumor Insight team delved into the front lines, capturing international advancements and witnessing China's contributions to the field of oncology on the global stage. Professor Cai-Cun Zhou from Tongji University Affiliated Shanghai Pulmonary Hospital delivered an important oral presentation at this conference (Abstract No: LBA33). In a live interview with "Tumor Insight," Professor Zhou shared insights into the research on the novel KRAS G12D inhibitor HRS-4642 for the treatment of late-stage solid tumor patients with KRAS G12D mutation, as well as thoughts and perspectives on the future direction of drug development. This article summarizes the relevant content for readers.
ESMO Big Shot Interview | Professor Xu Ruihua: Oncology in China Is Thriving, with a Record Number of Selected Papers

ESMO Big Shot Interview | Professor Xu Ruihua: Oncology in China Is Thriving, with a Record Number of Selected Papers

2024.02.22
The 2023 European Society for Medical Oncology (ESMO) Annual Congress was held in Madrid, Spain from October 20th to 24th. The Oncology Horizon team went deep into the front lines, capturing international advancements and witnessing the progress of cancer research in China on the global stage. Professor Xu Ruihua from Sun Yat-sen University Cancer Center delivered a significant oral presentation at this year's congress. In an interview with "Oncology Horizon," Professor Xu shared highlights from the field of gastrointestinal oncology at ESMO and provided insights into the congress. This article compiles relevant content for our readers.
“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

“CCHIO 2023 | Professor Zhang Jin: Classification Management and Precision Treatment of Breast Cancer Patients”

2024.02.21
Breast cancer is the most common malignancy among women globally, with an increasing incidence rate that poses a significant threat to women's health worldwide. Molecular typing aids in the precise classification and stratified treatment of breast cancer. The continuous development of immunotherapy and targeted therapy offers new treatment options for patients with different types. At the recent 2023 China Conference of Integrated Oncology (CCHIO 2023), "Tumor Watch" had the opportunity to interview Professor Zhang Jin from Tianjin Medical University Cancer Hospital at the venue. Professor Zhang discussed the current state of breast cancer research in China, reviewed the evolution of breast cancer treatment strategies, and shared insights into the precision treatment of patients with different types.